MediWound Ltd. (MDWD), enzymatic therapeutics for tissue repair, on Tuesday announced it will host a virtual Key Opinion Leader (KOL) event on January 8, 2025, at 10:00 AM ET.
The event will focus on EscharEx, an innovative biologic drug in late-stage development for chronic wound debridement, specifically targeting Venous Leg Ulcers (VLUs).
The event will feature three distinguished clinical experts: Dr. John C. Lantis II, Dr. Vickie R. Driver, and Dr. Robert J. Snyder.
These experts will discuss promising Phase II results of EscharEx, its effectiveness in wound debridement, and the upcoming Phase III VALUE study in VLUs. They will also highlight EscharEx's competitive advantages and its unique commercial opportunity, addressing the substantial unmet need for better treatment options in chronic wound care.
In addition, MediWound will share details on the upcoming Phase II/III study focused on diabetic foot ulcers (DFUs).
The virtual event will include a live Q&A session with MediWound's leadership team, providing an opportunity for participants to engage with experts and ask questions.
MDWD closed Tuesday's (Dec. 17, 2024) trading at $17.27, up 3.10%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.